(LON: MXCT) CEO Doug Doerfler sat down with Proactive at the BIO Investor Forum in San Francisco.
Doerfler says the company is making 'exciting progress' with its early-stage cancer drug developed using its CARMA technology.
The objective of a study of this kind is to assess whether the drug is safe and well-tolerated.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE